Drug intelligence / Profile preview

Ceftrigreen-S

Development stage
Unknown
Lead developer
Green Heart
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Ceftrigreen-S is an approved injectable fixed-dose combination antibiotic marketed by Green Heart for the treatment of serious bacterial infections caused by susceptible organisms. It contains ceftriaxone, a third-generation cephalosporin beta-lactam antibiotic that binds penicillin-binding proteins and inhibits bacterial cell wall synthesis, together with sulbactam, a beta-lactamase inhibitor that protects ceftriaxone from enzymatic degradation by susceptible bacterial beta-lactamases and broadens activity against beta-lactamase-producing strains. The product is administered by intravenous or intramuscular injection and is used for infections such as respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, meningitis, septicemia, and bone infections.

Brand names
Ceftrigreen-S
Other names
ceftriaxone + sulbactamceftriaxone sodium + sulbactam sodium
02

Targets

β-lactamasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Ceftrigreen-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceftrigreen-S.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call